PROTAC BRD4 Degrader-2

PROTAC BRD4 Degrader-2 is an efficacious degrader of PROTAC BRD4(BRD4 BD1,IC50 of 14.2 nM).

PROTACBRD4 Degrader-26 (PROTAC-2) is a photo-regulated PROTAC designed to degrade BRD4, achieving 80% degradation efficiency at a concentration of 1 μM. This compound can be inactivated by ultraviolet light.

PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits robust antitumor activity in mouse xenograft models, serving as a research tool for cancer [1].

PROTAC BRD4 Degrader-29 (compound 7a) is a potent BRD4 PROTAC degrader with a DC50 of 89.4 nM, playing a significant role in cancer research.

PROTAC BRD4 Degrader-28 (Compound 4) is a PROTAC degrader specifically targeting BRD4, and it holds potential for cancer research.

PROTAC BRD4 Degrader-23 (compound 17) is an effective visible light-controlled degrader. When exposed to 405 nm light, it can inhibit the proliferation of tumor cells.

PROTAC BRD4 Degrader-21 (Comp 74), a potent BRD4 degrader, has shown significant inhibition of tumor growth in mouse xenograft models, indicating its potential for anticancer research [1].

PROTAC BRD4 Degrader-22 (Compd 44h) is a PROTAC-based degrader targeting BRD4, with a pDC50 of 9.2 in MOLT4 cells over 24 hours [1].

PROTAC BRD4 Degrader-20 (compound 195) is a bifunctional degrader of BRD4 [1].

PROTAC BRD4 Degrader-27 is a selective PROTAC targeting BRD4, distinguished from BRD2/BRD3. This compound is composed of the E3 ubiquitinase ligand Thalidomide-4-OH, the PROTAC Linker γ-Aminobutyric acid, and the PROTAC target protein ligand PROTAC BRD4 ligand-3. The active control for this target protein ligand is Mivebresib, while the conjugate of the E3 ubiquitin ligase ligand and Linker is identified as Pomalidomide 4'-alkylC3-acid.

Lenalidomide-PEG1-azide is an E3 ligase ligand-linker complex comprising a cereblon ligand and linker, suitable for synthesising PROTACs and click chemistry reactions.

PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent, selective degrader of BET proteins BRD4 and BRD2, achieving rapid, reversible, and unexpectedly selective elimination compared to BRD3. It effectively suppresses solid tumors with minimal cytotoxic effects and comprises a BET inhibitor, a connecting linker, and thalidomide as the ligand for cereblon (CRBN)/cullin 4A[1].

4-[(1E)-2-Nitroethenyl]benzoic acid functions as an E3 ligase ligand and is utilized in the synthesis of PROTAC BRD4 Degrader-38.

PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor with IC50 values of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively, effectively degrading the BRD4 protein in PC3 prostate cancer cells[1].

ARV-771 is an effective BET degrader based on PROTAC technology. The Kd for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1) and BRD4(2) are 34 and 4.7 respectively. , 8.3, 7.6, 9.6 and 7.6 nM.

PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker conjugate for PAC. PROTAC BRD4 Degrader-5-CO-PEG3-N3 comprises the BRD4 degrader GNE-987 linked through a PEG-based spacer to enable modular bioconjugation. PROTAC BRD4 Degrader-5-CO-PEG3-N3 functions as a click-chemistry reagent containing an azide group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-bearing molecules. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can also react through strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO- or BCN-containing compounds, thereby supporting targeted PROTAC assembly and bioconjugation for chemical biology and drug-discovery applications.